DexTech Medical AB: Annual Report 2021-07-01 - 2022-06-30

The Board of Directors and the CEO of Dextech Medical AB (DexTech), org.nr. 556664-6203, with its registered office in Stockholm, may hereby submit annual accounts for the financial year 2021-07-01 - 2022-06-30.

For more information about DexTech, please contact:

Gösta Lundgren - CFO

DexTech Medical AB

Phone: +46 (0) 707104788

E-post: [email protected]

 

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful clinical phase II study has been conducted with OsteoDex where the result shows high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to outlicense each drug candidate no later than after completing the phase II study. DexTech Medical AB is listed on Spotlight Stock Market.